Mayur Kumar
Impact in
- Infectious Diseases top 2%
- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
- Internal Medicine top 10%
- Venous Thromboembolism Diagnosis and Management
Papers in
-
- COVID-19 Clinical Research Studies 9
- SARS-CoV-2 and COVID-19 Research 1
- Oncology 2
- COVID-19 and healthcare impacts 1
- Co-authors
- Ray Mathew (1 shared paper)Shyam Menon (1 shared paper)Gibran Timothy Yusuf (1 shared paper)
- Journals
- The Lancet (5 papers)EClinicalMedicine (1 paper)The Lancet Diabetes & Endocrinology (1 paper)The Lancet Child & Adolescent Health (1 paper)Cancer Cell (1 paper)
- Partner nations
- United KingdomVietnamNepal
In The Last Decade
Mayur Kumar
14 papers receiving 1.3k citations
Mayur Kumar's Hit Papers
Peers
Comparison fields: 5 of 79
- Infectious Diseases 1k
- Internal Medicine 27
- Oncology 84
- Hematology 37
- Statistics and Probability 34
Countries citing papers authored by Mayur Kumar
This map shows the geographic impact of Mayur Kumar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mayur Kumar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mayur Kumar more than expected).
Fields of papers citing papers by Mayur Kumar
This network shows the impact of papers produced by Mayur Kumar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mayur Kumar. The network helps show where Mayur Kumar may publish in the future.
Co-authors
The 3 scholars most cited alongside Mayur Kumar, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial Hit paper breakdown → | 2021 | 393 |
| 2 | Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2022 | 282 |
| 3 | Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis Hit paper breakdown → | 2022 | 231 |
| 4 | 2021 | 213 | |
| 5 | 2021 | 84 | |
| 6 | Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2023 | 84 |
| 7 | 2023 | 25 | |
| 8 | 2024 | 24 | |
| 9 | 2019 | 10 | |
| 10 | 2019 | 10 | |
| 11 | 2024 | 5 | |
| 12 | 2025 | 5 | |
| 13 | 2025 | 2 | |
| 14 | 2004 | 1 |
About Mayur Kumar
Mayur Kumar is a scholar working on Infectious Diseases, Oncology, Otorhinolaryngology, Surgery and Hepatology, having authored 14 papers that have together received 1.4k indexed citations. Recurring topics across this work include COVID-19 Clinical Research Studies (9 papers), COVID-19 and healthcare impacts (1 paper), Head and Neck Cancer Studies (1 paper), Abdominal Trauma and Injuries (1 paper), Radiation Dose and Imaging (1 paper), Medical Case Reports and Studies (1 paper), SARS-CoV-2 and COVID-19 Research (1 paper) and Kawasaki Disease and Coronary Complications (1 paper). The work is most often cited by research in Infectious Diseases (1k citations), Internal Medicine (27 citations), Oncology (84 citations), Hematology (37 citations) and Statistics and Probability (34 citations). Mayur Kumar has collaborated with scholars based in United Kingdom, Vietnam and Nepal. Frequent co-authors include Ray Mathew, Shyam Menon and Gibran Timothy Yusuf. Their work appears in journals such as The Lancet, EClinicalMedicine, The Lancet Diabetes & Endocrinology, The Lancet Child & Adolescent Health and Cancer Cell.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.